Identifying regulators of prostate cancer cell survival may lead to new therapeutic strategies for prostate cancer. We now report prevalent activation of transcription factor Stat5 in human prostate cancer and provide novel evidence that blocking activation of Stat5 in human prostate cancer cells leads to extensive cell death. Specifically, Stat5 was activated in 65% of human prostate cancer specimens examined based on nuclear location of tyrosine phosphorylated Stat5. with evidence of a Caspase-9 dependent mechanism. We propose that blocking Stat5 function may represent a novel therapeutic approach for prostate cancer.
INTRODUCTION
Prostate cancer typically progresses to androgen-independent growth after androgen-ablation therapy. Identification of androgen-independent proteins that control prostate cancer cell survival may lead to more effective therapies. Using long-term organ cultures of human and rat prostate tissues, we have documented direct effects of prolactin (Prl) as a mitogen and survival factor for prostate epithelium (1) (2) (3) (4) . These observations have been complemented by demonstration of massive hyperplasia of prostates in transgenic mice over-expressing Prl (5, 6) , as well as reduced prostate sizes in Prl-null mice (7) . Importantly, we have also shown local production of Prl (1, 8) and expression of Prl-receptors in prostate epithelium (1, 9) and, thereby, provided evidence for an autocrine loop of Prl action in prostate. Downstream of Prl-receptor activation, we have demonstrated that Stat5 is a key signaling protein in normal rat prostate epithelium (10) , and that deficiency of Stat5 in Stat5a-null mice is associated with defective prostate tissue architecture (11) .
Stat5 is one of 7 members of the Stat family of transcription factors in mammals (12) , and consists of two distinct, but highly homologous, gene products; the 94-kDa Stat5a and 92-kDa Stat5b (13, 14) . In response to Prl, Stat5a and Stat5b become activated by phosphorylation on residue Tyr694 and Tyr 699, respectively, in the C-terminal domain predominantly by Janus tyrosine kinase-2 (Jak2), which is preassociated with the cytoplasmic domain of the Prl receptor (15) . Tyrosine phosphorylated Stat5 proteins dimerize and translocate to the nucleus, where they bind to specific response elements of target gene promoters to regulate transcription (16) .
Based on our previous findings of a survival function of Prl in normal prostate epithelium (4) , an autocrine production of Prl by prostate epithelial cells (1, 8) , and the glandular defect of the prostates of Stat5a knock-out mice (11) , we hypothesized that Stat5 may act as a survival protein in human prostate cancer, and that blocking Stat5 function could induce death of prostate cancer cells. We investigated activation of Stat5 in 40 human prostate cancer samples by immunohistochemical analysis using activation-state specific anti-phosphoTyrStat5 antibody.
To specifically block Stat5 activity in human prostate cancer cells, we created a dominantnegative mutant of Stat5 (DNStat5) in an adenoviral transfer vector. In this work we demonstrate that transcription factor Stat5 is activated in a significant number of human prostate cancer specimens and that blocking Stat5 activity induces extensive apoptosis of prostate cancer cells.
MATERIALS AND METHODS
Cell Culture. CWR22Rv, LnCap, and PC-3 cells (ATCC, Manassas, VA) were cultured in RPMI-1640 medium (Biofluids, Gaithersburg, MD) and T47D cells (ATCC) in DMEM containing 10% fetal calf serum, 2 mM L-glutamine, and penicillin-streptomycin (50 IU/ml and 50 µg/ml, respectively) at 37 ºC with 5% CO 2 . LnCap cells were cultured in the presence of 1 nM dihydrotestosterone (5±-androstan-17²-ol-3-one; Sigma, Chemical Co., MO).
Immunohistochemical Detection of Phosphorylated Stat5 in Human Prostate Cancer.
Tissue sections of formalin-fixed prostate cancer samples from 40 patients were immunostained for activated Stat5 as described previously (17) . Briefly, tissue sections were de-paraffinized in xylene followed by re-hydration in graded alcohol. To unmask the epitopes, the slides were microwave-treated with antigen retrieval solution AxAR1 (Advantex BioReagents, Conroe, TX) or AxAR2 for use with anti-pTyrStat5 mAb or anti-panStat5 mAb, respectively. Endogenous peroxidase activity was blocked by incubating the slides in 0.3% hydrogen peroxide, and the tissue sections were incubated in normal goat serum (BioGenex Laboratories Inc., San Ramon, CA) for 2 h to block unspecific binding of immunoglobulins (IgGs). The anti-pTyrStat5 mAb was diluted in 1% BSA in PBS at a final concentration of 0.6 ¼g/ml (Advantex BioReagents).
The anti-panStat5 mAb was used at a concentration of 2 ¼g/ml (Advantex Bioreagents).
Antigen-antibody complexes were detected using anti-mouse biotinylated goat secondary antibody followed by streptavidin-horseradish-peroxidase complex (BioGenex). 3,3'-diaminobenzidine was used as chromogen and hematoxylin as counterstain. For negative controls, parallel slides were immunostained with subtype-specific mouse IgG, and lactating human mammary gland was used as positive control tissue (17) .
Generation of adenovirus for gene delivery of dominant-negative and wild-type Stat5.
Expression vector for murine Stat5a (pXM-Stat5a) was kindly provided by Xiuwen Liu and Lothar Hennighausen (National Institutes of Health, Bethesda, MD) (14) . A dominant-negative (DN) variant of Stat5 (Stat5a∆713) was derived by truncation after amino acid residue Ala713 of pXM-Stat5a, using a PCR fragment generated using 5-TAATACGACTCACTATAGGG-3 (sense) and 5-GCTCTAGACTAGGCATCTGTGGATGCATTG-3 (antisense) primers, followed by EcoRI and XbaI digestion, and subcloning into the EcoRI-XbaI-digested pXMStat5a. The DNA sequence of the resulting construct pXM-Stat5a∆713 was verified before use.
The ability of our DNStat5 (Stat5a∆713) expression construct to completely suppress both Stat5a and Stat5b-mediated transcriptional activation has been reported (18) . Replication-defective human adenovirus (Ad5) carrying wild-type Stat5 (WTStat5) or DNStat5 was generated using Cells were scraped and centrifuged at 500 x g, and cytoplasmic fractions containing activated Caspases were transferred to microtiter plates. Caspase-3 substrate (DEVD) or Caspase-9 substrate (LEHD) labeled with the fluorescent molecule 7-amino-4-trifluoromethyl coumarin (AFC) were added to the samples. Free fluorescent AFC was generated proportionally to the amount of activated Caspase in the cell lysate due to proteolytic cleavage of the substrate and determined fluorometrically at 505 nm.
RESULTS AND DISCUSSION
Stat5 is frequently activated in human prostate cancer. We have recently described a highly sensitive in situ detection method for activation of Stat5 in paraffin embedded tissue which is based on immunohistochemical detection of phosphorylated Stat5 that is localized within the cell nucleus (10, 17) . This method, complemented with immunohistochemical detection of nuclear Stat5 protein, was applied to a material of 40 human prostate cancer specimens, and significant activation of Stat5 was detected in 65% (26 of 40) of primary human prostate cancer specimens of various Gleason scores. Representative samples illustrating Stat5 activation by either phosphotyrosine detection, or nuclear anti-Stat5 detection, within malignant human prostate epithelia are presented (Fig. 1A, panels a and b, respectively) . In contrast, Stat5 phosphotyrosine staining was negative (Fig. 1A, panel c) 17) , and parallel sections of lactating human breast stained with subtype-specific mouse IgG were negative (Fig. 1A , panels d and e, respectively). To determine whether blocking endogenous Stat5 activity would induce death of human prostate cancer cells, we first examined the effect of increasing doses of AdDNStat5 on the viability of the androgen-independent CWR22Rv cell line. For the initial cell viability studies we used an assay determining the metabolic activity of the cells. CWR22Rv cells were cultured to 70% confluence in 96-well plates, and exposed for 90 min to AdDNStat5 or AdWTStat5 at doses up to MOI 10, after which the virus was diluted 6-fold in culture medium as described. After 96 h of infection, cells were analyzed for cell viability. A marked and dose-dependent effect of the expression of DNStat5 on cell viability was observed, with detectable suppression at MOI 2.5, and suppression of cell viability by more than 90% at MOI 10 (Fig.1C) . In contrast, cells infected with AdWTStat5 or AdLacZ did not show significant loss of viability (Fig. 1C) 1D, panel b) , which are morphological changes consistent with apoptotic cell death. In contrast, there was no evidence of reduced cell viability in response to AdWTStat5 (Fig. 1D, panel a) .
Stat5 is activated in CWR22Rv and
Likewise, AdDNStat5, but not AdWTStat5, induced cell death also in the androgen-sensitive human prostate cancer cell line, LnCap (Fig. 1D, panels c and (Fig. 1E) . Figure 1E also indicates that cellular levels of DNStat5 and WTStat5 delivered by the respective adenoviral vectors are comparable, supporting the notion that the selective cell death observed in response to AdDNStat5 is due to its specific dominant-negative characteristics and not caused by other nonspecific mechanisms. In contrast, there were no signs of cell death in PC-3 cells after 72 h exposure to AdDNStat5 at MOI 32 as judged from cell morphology (data not shown).
To further verify that DNStat5-induced killing of prostate cancer cells was due to apoptotic cell death, prostate cancer cells were analyzed for DNStat5-induced fragmentation of DNA.
CWR22Rv cells were exposed to AdDNStat5 and a set of controls at MOI 8 for 48 h. A selective effect of DNStat5 on induction of DNA fragmentation was observed, as analyzed by an enzymelinked immunosorbent assay (ELISA) of nucleosomal DNA fragments ( Fig. 2A, panel a) . On average, a seven-fold increase in nucleosomal DNA fragmentation was detected in cells exposed to AdDNStat5 over that detected in WTStat5 expressing cells (6 repeats, each with 3 replicates/treatment group). Furthermore, DNStat5-induced death of LnCap cells was also associated with DNA fragmentation, as evidenced by a consistent and more than six-fold increase in DNA fragmentation over levels in AdWTStat5 treated cells on day 3 at MOI 32 ( Apoptotic cell death of prostate cancer cells expressing DNStat5 was also verified by cell cycle analysis. In both CWR22Rv and LnCap cells expressing DNStat5, but not in cells expressing AdWTStat5, extensive DNA fragmentation was detected in the form of a large fraction of hypodiploid cell fragments (Fig. 2B) . In CWR22Rv cells, this proportion was estimated to be approximately 8% of total cellular DNA at Day 3 of AdDNStat5 infection using MOI of 8, which was 8-fold higher than that observed in parallel AdWTStat5-treated cells (0.9%). In LnCap cells, the fraction of cell fragments with hypodiploid DNA content increased 6-fold from 1.3% in AdWTStat5-treated cells to approximately 8% in DNStat5-treated cells. Mock-infected cells and cells infected with empty control virus or AdLacZ were used as controls, and the fraction of hypodiploid cells consistently remained below 1.3% (data not shown).
DNStat5-induced apoptosis of CWR22Rv and LnCap cells involves Caspase-3 activation.
Proteolytic enzymes of the caspase family are critical mediators of programmed cell death. A central role has been ascribed to Caspase-3 as a key executor of a major category of apoptotic cell death (19) . To determine whether apoptosis in prostate cancer cells induced by expression of DNStat5 is mediated by activation of Caspase-3, we analyzed Caspase-3 activation by a specific Caspase-3 enzymatic assay. Exposure of CWR22Rv or LnCap cells to AdDNStat5 for 36 h or 48 h, respectively, activated Caspase-3 in both cell lines (Fig. 2C) . Specifically, in CWR22Rv cells, activation of Caspase-3 was increased 8-fold in cells expressing DNStat5 compared to AdWTStat5-infected cells. In LnCap cells the corresponding increase was approximately 2-fold (3 repeats each with 3-replicates/treatment group). Therefore, we conclude that DNStat5-induced apoptosis in both CWR22Rv and LnCap human prostate cancer cells involved activation of Caspase-3.
Caspase-3 mediated apoptosis may be induced through upstream activation of Caspase-9 in a Cytochrome C-dependent manner, or through Caspase-9 independent mechanisms (20) . Since suppression of Stat5 activation in CWR22Rv and LnCap cells induced activation of Caspase-3, we wanted to determine whether DNStat5-induced activation of Caspase-3 involved activation of Caspase-9. Caspase-9 activity was monitored in response to DNStat5 in both CWR22Rv and LnCap cells for up to 72 h. A 6-fold induction of Caspase-9 was detected at 36 h in CWR22Rv cells expressing DNStat5 (Fig. 2D) . In LnCap cells, the same trend was observed, but the effect was less striking (data not shown). We conclude that DNStat5-induced cell death in CWR22Rv cells is mediated by Caspase-3 through a Caspase-9 dependent mechanism. Caspase-9 activation further indicates a cytochrome C/Apaf-1 dependent apoptotic process (20) . Ongoing work aims to define the exact sequence of molecular events that are involved in DNStat5-induced prostate cancer cell apoptosis.
The prevalent detection of activated Stat5 in primary human prostate cancer specimens indicates that Stat5 is a candidate therapeutic target in a high proportion of prostate cancers. A recent study by Gao and colleagues indicated that in human prostate tissue homogenates there was only low level of Stat5 binding to an oligonucleotide probe corresponding to the Stat5 response element of the rat beta-casein promoter in electrophoretic mobility shift assays (21) . It is possible that prostate cancer-specific or stromal factors interfere with binding of Stat5 to this promoter when whole tissues are homogenized. In this regard, using our highly sensitive in situ technique, which detects Stat5 activation at a single cell level, we have recently demonstrated that Stat5 is activated in normal human and mouse mammary epithelial cells outside of pregnancy, an activity that is difficult to detect by EMSA using tissue homogenates of whole mammary glands (17) .
The present work suggests that blocking activation of Stat5 in human prostate is a potential new therapeutic approach. Delivery of suicide genes into cancer cells is hampered by lack of effective delivery systems, but gene therapeutic delivery systems are constantly improving and involve both viral and non-viral strategies (22, 23) . Prl-receptor associated signaling pathways are of particular interest, because Prl is produced locally in prostate epithelium indicating an autocrine loop of Prl action in prostate (1, 8) . In addition to Jak2, other tyrosine kinases, such as Jak1, Jak2, Jak3 or Tyk2, as well as members of the Src tyrosine kinase family, or receptor tyrosine kinases, are also possible Stat5 kinases in prostate cancer (24) .
We show in this work using in situ detection of phosphorylated and nuclear Stat5 that Stat5 was activated in a majority of prostate cancer specimens examined. This suggests that inhibition of Stat5 as a therapeutic approach could have a broad usefulness in the treatment of prostate cancer.
The observation that both androgen-refractory CWR22Rv and androgen-sensitive LnCap cells responded to suppression of Stat5 with cell death, implies that apoptosis induced by blocking the activation of Stat5 is independent of responsiveness to androgens. Furthermore, the correlation between endogenous Stat5 activation in prostate cancer cell lines and their sensitivity to DNStat5 suggests that immunohistochemical detection of activated Stat5 in prostate cancer may predict responsiveness to this therapeutic strategy. 
